pasireotide acetate

Pasireotide acetate is a synthetic, long-acting cyclic hexapeptide that acts as a somatostatin analog. It binds with high affinity to multiple somatostatin receptors (SSTR1, SSTR2, SSTR3, and SSTR5), with notably higher affinity for SSTR1, SSTR3, and SSTR5 than other somatostatin analogs. Pasireotide inhibits the secretion of adrenocorticotropic hormone (ACTH) and subsequently reduces cortisol production, which is central to its use in Cushing’s disease. It also reduces secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), leading to its use in acromegaly. The drug is indicated for adult patients with Cushing's disease or acromegaly for whom pituitary surgery is not an option or has not been curative. The developer of pasireotide is Novartis, and it is marketed in the U.S. by Recordati Rare Diseases Inc. under the brand names Signifor and Signifor LAR[1][2][3][4][5][8].

Brand names

SigniforSignifor LAR

Other names

pasireotidePasiŕeotidepasireotidumcyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-)